Upcoming market catalysts in the fourth quarter of 2025 include US approval decisions on navepegritide for achondroplasia, relacorilant for Cushing syndrome and ziftomenib for acute myeloid leukaemia (AML).

Enjoying our latest content?
Login or create an account to continue Access the most recent journalism from Nature's award-winning team Explore the latest features & opinion covering groundbreaking research

or

Competing Interests

The author declares no competing interests.